Submitted:
05 October 2023
Posted:
12 October 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and methods
2.1. Statistical analysis
3. Results and discussion
4. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Conflicts of Interest
References
- Aldossary, S.A. Review on pharmacology of cisplatin: clinical use, toxicity and mechanism of resistance of cisplatin. Biomed. Pharmacol. J. 2019, 12, 7–15. [Google Scholar] [CrossRef]
- Jadon., A.S.; Bhadauriya, P.; Sharma, M. An integrative review of cisplatin: the first metal anti-tumor drug. Journal of Drug Delivery and Therapeutics. (JDDT) 2019, 9, 673–677. [Google Scholar]
- Dasari, S.; Njiki, S.; Mbemi, A.; Yedjou, C.G.; Tchounwou, P.B. Pharmacological effects of cisplatin combination with natural products in cancer chemotherapy. Int. J. Mol. Sci. 2022, 23, 1–25. [Google Scholar] [CrossRef]
- Tchounwou, P. B.; Dasari, S.; Noubissi, F. K.; Ray, P.; Kumar, S. Advances in our understanding of the molecular mechanisms of action of cisplatin in cancer therapy. J. Exp. Pharmacol. 2021, 13, 308–323. [Google Scholar] [CrossRef] [PubMed]
- Stone, J.B.; DeAngelis, L.M. Cancer Treatment-induced neurotoxicity: a focus on newer treatments. Nat. Rev. Clin. Oncol. 2016, 13, 92–105. [Google Scholar] [CrossRef] [PubMed]
- Hashem, R.M.; Safwar, G.M.; Rashed, L.A.; Bakry, S. Biochemical findings on cisplatin-induced oxidative neurotoxicity in rats. Int J Adv.Res. 2015, 3, 1222–1234. [Google Scholar]
- Yang, H.; Villani, R.M.; Wang, H.; Simpson, M.J.; Roberts, M.S.; Tang, M.; Liang, X. The role of cellular reactive oxygen species in cancer chemotherapy. Journal of Experimental and Clinical Cancer Research. 2018, 37, 1–10. [Google Scholar] [CrossRef]
- Habtemariam, S. Modulation of reactive oxygen species in health and disease. Antioxidants 2019, 8, 513–516. [Google Scholar] [CrossRef] [PubMed]
- Sidharta, B.R.A.; Purwanto, B.; Wasita, B.; Widyaningsih, V.; Soetrisno, O.E. Single or Divided Administration of Cisplatin Can Induce Inflammation and Oxidative Stress in Male Sprague-Dawley Rats. Indones Biomed J. 2022, 14, 164–171. [Google Scholar] [CrossRef]
- Singh, R.; Manna, P.P. Reactive oxygen species in cancer progression and its role in therapeutics. Explore Med. 2022, 3, 43–57. [Google Scholar] [CrossRef]
- Gaschler M., M.; Stockwell, B.R. Lipid peroxidation in cell death. Biochem. and Biophys. Res. Commun. 2017, 482, 419–425. [Google Scholar] [CrossRef]
- Mirzaei, S.; Hushmandi, K.; Zabolian, A.; Saleki, H.; Torabi, S.M.R.; Ranjbar, A.; SeyedSaleh, S.; Sharifzadeh, S.O.; Khan, H.; Ashrafizadeh, M.; et al. Elucidating role of reactive oxygen species (ROS) in cisplatin chemotherapy: A focus on molecular pathways and possible therapeutic strategies. Molecules 2021, 26, 1–37. [Google Scholar] [CrossRef]
- Hauck, A. K.; Bernlohr, D. A. Oxidative stress and lipotoxicity. Journal of Lipid Research 2016, 57, 1977–1986. [Google Scholar] [CrossRef]
- Casares, C.; Ramı´rez-Camacho, R.; Trinidad, A.; Rolda´n, A.; Jorge, E.; Garcı´a-Berrocal, J. R. Reactive oxygen species in apoptosis induced by cisplatin: review of physiopathological mechanisms in animal models. Eur Arch Otorhinolaryngol 2012, 269, 2455–2459. [Google Scholar] [CrossRef] [PubMed]
- Cook, A. M.; McDonnella, A. M.; Lakea, R.A.; Nowaka, A. K. Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies. Oncoimmunology 2016, 5, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Chow, R.; Warr, D.G.; Navari, R.M.; Tsao, M.; Milakovic, M.; Popovic, M.; Chiu, L.; Lam, H.; DeAngelis, C. Efficacy and safety of 1-day versus 3-day dexamethasone for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. J Hosp Manag Health Policy 2018, 2, 1–13. [Google Scholar] [CrossRef]
- Sverediuk, Y.A.; Pelykh, V.Y. Changes of lipid oxidation products content in ventricles of the rat heart as a result of electrolyte-steroid cardiomyopathy and correction of this condition. Journal of Education, Health and Sport. 2020, 10, 272–280. [Google Scholar] [CrossRef]
- Alahmar, A.T.; Al Jothery, A.H.T.; Al-Daami, Q.J.; Abbas, A.; Al-Hassnawi, A.T.S. The effect of coenzyme Q10 on dexamethasone-induced oxidative stress in rats testes. Med J Babylon 2023, 20, 130–135. [Google Scholar]
- Blobel, G.; Potter, V.R. Nuclei from rat liver: isolation method that combines purity with high yield. Science 1966, 154, 1662–1665. [Google Scholar] [CrossRef] [PubMed]
- Volchegorsky, I.A.; Nalimov, A.G.; Yarovinsky, B.G.; Livshits, R.I. Comparison of different approaches to the determination of lipid peroxidation products in heptane-isopropanol blood extracts. Question. honey. chemistry 1989, 35, 127–131, (Article in Russian). [Google Scholar]
- Plathow, C.H.; Weber, W.A. Tumor Cell Metabolism Imaging. Journal of Nuclear Medicine 2008, 4, 43S–63S. [Google Scholar] [CrossRef] [PubMed]



|
Tissues |
Unsaturated fatty acids in heptane phase | |||
| Baseline without treatment | After cisplatin action | After dexamethasone action | After cisplatin and dexamethasone combined action | |
| Brain | 28.00±0.36 | 29.00±0.92 | 27.80±1.25 | 25.50±0.86 |
| Kidney | 9.00±0.08 | 10.00±0.02* | 9.90±0.46* | 8.73±0.42 |
| Unsaturated fatty acids in isopropanol phase | ||||
| Brain | 15.30±0.85 | 20.00±0.9* | 18.30±0.50* | 25.00±0.6* |
| Kidney | 4.34±0.15 | 5.47±0.22* | 5.87±0.28* | 7.26±0.09* |
|
Tissues |
Diene conjugates in heptane phase | |||
| Baseline without treatment | After cisplatin action | After dexamethasone action | After cisplatin and dexamethasone combined action | |
| Brain | 4.00±0.07 | 12.00±0.37* | 4.45±0.12* | 4.40±0.11* |
| Kidney | 1.12±0.10 | 4.81±0.24* | 2.38±0.11* | 1.46±0.07* |
| Diene conjugates in isopropanol phase | ||||
| Brain | 3.00±0.27 | 7.10±0.32* | 6.70±0.30* | 11.4±0.12* |
| Kidney | 1.52 ±0.05 | 2.80±0.10* | 2.33±0.03* | 3.30±0.08* |
| Triene conjugates in heptane phase | ||||
| Baseline without treatment | After cisplatin action | After dexamethasone action | After cisplatin and dexamethasone combined action | |
| Brain | 1.83±0.08 | 4.63±0.21* | 2.22±0.10* | 2.61±0.12* |
| Kidney | 0.56±0.03 | 1.73±0.04* | 1.32±0.06* | 1.10±0.04* |
| Triene conjugates in isopropanol phase | ||||
| Brain | 2.15±0.10 | 5.08±0.24* | 4.00±0.18* | 6.50±0.30* |
| Kidney | 1.40±±0.07 | 2.10±0.10* | 1.78±0.08* | 2.90±0.03* |
|
Experimental groups |
Heptane phase | |||||||
| Brain nuclei | Kidney nuclei | |||||||
| 232/220 | 278/220 | 232/220 | 278/220 | |||||
| Value of oxidation index | % | Value of oxidation index | % | Value of oxidation index | % | Value of oxidation index | % | |
| Baseline | 0.143 | 100 | 0.065 | 100 | 0.124 | 100 | 0.062 | 100 |
| CP | 0.414 | 290 | 0.160 | 246 | 0.410 | 331 | 0.173 | 279 |
| DEX | 0.160 | 112 | 0.080 | 123 | 0.240 | 194 | 0.133 | 215 |
| CP+DEX | 0.172 | 120 | 0.102 | 157 | 0.167 | 135 | 0.126 | 203 |
| Isopropanol phase | ||||||||
| Baseline | 0.196 | 100 | 0.140 | 100 | 0.350 | 100 | 0.322 | 100 |
| CP | 0.355 | 181 | 0.254 | 181 | 0.512 | 146 | 0.384 | 119 |
| DEX | 0.366 | 187 | 0.219 | 156 | 0.397 | 113 | 0.303 | 94 |
| CP+DEX | 0.456 | 233 | 0.260 | 185 | 0.455 | 130 | 0.400 | 124 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).